Thea
Thea Kalebic, Springfield, NJ US
Patent application number | Description | Published |
---|---|---|
20080219996 | Molecular Markers Associated with Bone Metastasis - This invention relates generally to the modulation of expression levels of bone sialoprotein (BSP) in tumors, especially a non-small cell lung cancer tumor, as an indicator of progression to bone metastasis. | 09-11-2008 |
20110312968 | METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS - The present invention relates to a method tor evaluating patterns to help-optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. Specifically, present invention relates to SHP1 and/or SHP2 as a biomarker for CML patients. | 12-22-2011 |
Thea Kalebic, East Hanover, NJ US
Patent application number | Description | Published |
---|---|---|
20110224224 | Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate - The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of | 09-15-2011 |
Thea Pugatsch, Maale Adumim IL
Patent application number | Description | Published |
---|---|---|
20100158973 | THERAPEUTIC USES OF CANNABIDIOL COMPOUNDS - The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as preventing the formation of heart scars. | 06-24-2010 |
Thea Sipila Inen-Malm, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20100135858 | Ink Composition and Oxygen Indicator - An ink composition comprising a redox compound as dye, a volatile agent as reducing agent, a polymer material as binder and a volatile solvent, wherein said ink composition has a viscosity of 3 to 150 mPas when said ink composition is used for printing. | 06-03-2010 |
Thea Sipiläinen-Malm, Espoo FI
Patent application number | Description | Published |
---|---|---|
20110136238 | OXYGEN INDICATOR - The invention relates to a dye composition comprising a dye, dye converter, binder, reducing agent, solvent and optionally basic agent. Further, the invention relates to a method for fabricating an oxygen indicator wherein a dye composition is applied over a substrate and reduced by heating, to an oxygen indicator fabricated by the method and to a package for detecting a leakage and/or variation in the oxygen content. | 06-09-2011 |